GH55 plus GH21 for advanced solid tumors with MAPK pathway changes
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs, GH55 and GH21, for people with advanced solid tumors that have changes in the MAPK signaling pathway (a cellular growth pathway). The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your cancer must be advanced or have spread, and have certain changes in the MAPK signaling pathway.
- You must have tried standard treatments that didn't work, or you can't take them, or they aren't available.
- You need at least one tumor that can be measured on scans.
- You must be in fairly good physical health (able to do daily activities with little help).
- Your major organs (like liver, kidneys, heart) need to work well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GH55, for people with advanced solid tumors that have a specific change in a group of genes called MAPK. It is for those who have tried other treatments or cannot have standard therapy. The goal is to see if the drug is safe and how well it works.
This trial tests a new combination of two targeted pills (GH21 and D-1553) for people with advanced solid tumors that have a specific KRAS G12C mutation, especially those who have already tried another KRAS G12C inhibitor. The goal is to see if the combo can shrink tumors more effectively.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, GH21 and D-1553, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination works better than each drug alone.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.